Antibody data
- Antibody Data
- Antigen structure
- References [8]
- Comments [0]
- Validations
- Western blot [1]
- Blocking/Neutralizing [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- AF234 - Provider product page
- Provider
- R&D Systems
- Product name
- Human ErbB3/Her3 Antibody
- Antibody type
- Polyclonal
- Description
- Immunogen affinity purified. Detects human ErbB3 in direct ELISAs and Western blots. In direct ELISAs, less than 1% cross-reactivity with recombinant human (rh) EGF R, rhErbB2, and rhErbB4 is observed.
- Reactivity
- Human
- Host
- Goat
- Conjugate
- Unconjugated
- Antigen sequence
P21860
- Isotype
- IgG
- Vial size
- 100 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references Soluble HER3 predicts survival in bladder cancer patients.
Cellular effects of HER3-specific affibody molecules.
A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation.
Human epidermal growth factor receptor (HER-1:HER-3) Fc-mediated heterodimer has broad antiproliferative activity in vitro and in human tumor xenografts.
Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer.
FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival.
Neuregulin-1-beta1 enters brain and spinal cord by receptor-mediated transport.
Neuregulin-1-beta1 enters brain and spinal cord by receptor-mediated transport.
Memon AA, Gilliver SC, Borre M, Sundquist J, Sundquist K, Nexo E, Sorensen BS
Oncology letters 2018 Feb;15(2):1783-1788
Oncology letters 2018 Feb;15(2):1783-1788
Cellular effects of HER3-specific affibody molecules.
Göstring L, Malm M, Höidén-Guthenberg I, Frejd FY, Ståhl S, Löfblom J, Gedda L
PloS one 2012;7(6):e40023
PloS one 2012;7(6):e40023
A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation.
Lin SH, Cheng CJ, Lee YC, Ye X, Tsai WW, Kim J, Pasqualini R, Arap W, Navone NM, Tu SM, Hu M, Yu-Lee LY, Logothetis CJ
Oncogene 2008 Sep 4;27(39):5195-203
Oncogene 2008 Sep 4;27(39):5195-203
Human epidermal growth factor receptor (HER-1:HER-3) Fc-mediated heterodimer has broad antiproliferative activity in vitro and in human tumor xenografts.
Sarup J, Jin P, Turin L, Bai X, Beryt M, Brdlik C, Higaki JN, Jorgensen B, Lau FW, Lindley P, Liu J, Ni I, Rozzelle J, Kumari R, Watson SA, Zhang J, Shepard HM
Molecular cancer therapeutics 2008 Oct;7(10):3223-36
Molecular cancer therapeutics 2008 Oct;7(10):3223-36
Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer.
Lin SH, Lee YC, Choueiri MB, Wen S, Mathew P, Ye X, Do KA, Navone NM, Kim J, Tu SM, Yu-Lee LY, Logothetis CJ
Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Jun 15;14(12):3729-36
Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Jun 15;14(12):3729-36
FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival.
Kunii K, Davis L, Gorenstein J, Hatch H, Yashiro M, Di Bacco A, Elbi C, Lutterbach B
Cancer research 2008 Apr 1;68(7):2340-8
Cancer research 2008 Apr 1;68(7):2340-8
Neuregulin-1-beta1 enters brain and spinal cord by receptor-mediated transport.
Kastin AJ, Akerstrom V, Pan W
Journal of neurochemistry 2004 Feb;88(4):965-70
Journal of neurochemistry 2004 Feb;88(4):965-70
Neuregulin-1-beta1 enters brain and spinal cord by receptor-mediated transport.
Kastin AJ, Akerstrom V, Pan W
Journal of neurochemistry 2004 Feb;88(4):965-70
Journal of neurochemistry 2004 Feb;88(4):965-70
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- Detection of Human ErbB3/Her3 by Western Blot. Western blot shows lysates of MCF-7 human breast cancer cell line. PVDF Membrane was probed with 1 µg/mL of Goat Anti-Human ErbB3/Her3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF234) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF019). A specific band was detected for ErbB3/Her3 at approximately 180kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 8.
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- Cell Proliferation Induced by NRG1-beta 1/HRG1-beta 1 and Neutralization by Human ErbB3/Her3 Antibody. Recombinant Human NRG1-beta 1/HRG1-beta 1 Extracellular Domain (Catalog # 377-HB) stimulates proliferation in the MCF-7 human breast cancer cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human NRG1-beta 1/HRG1-beta 1 Extracellular Domain (10 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human ErbB3/Her3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF234). The ND50 is typically 0.125-0.5 µg/mL.